Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
|Videos|February 4, 2022
Pharmaceutical Executive Roundtable: Future Shaping in Sales and Marketing: Sales Reps and Digital vs. In Person Approaches – Part 1
In this two-part segment, members of the panel discuss how the tradition pharma sales force has entered a phase in which they have to evolve, but what is the digital/in-person balance and how will the sales role change?
Advertisement
Advertisement
Related to this article
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Shionogi’s Dr. Draica on why preventative antivirals matter — and how its HIV and flu prevention heritage shaped XOCOVA’s post-exposure focus.
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
Brox.AI’s Hamish Brocklebank on the three approaches to digital twins in pharma — and why only one-to-one clones of real individuals deliver true accuracy.
Shionogi’s Dr. Draica on how XOCOVA blocks viral replication between exposure and symptoms — and why it works even with prior immunity.
Shionogi’s Dr. Draica on why COVID-19 still matters — and why the window between exposure and symptoms is where XOCOVA can intervene.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
3
FDA Approves Ilumya for Adults With Active Psoriatic Arthritis
4
Closing the Pediatric Evidence Gap
5